Home
Issues
Aim and Scope
Open Access
Editorial Board
Indexing
Why publish with us
Contact Us
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Special publications & Reprints
Authorship & COI
Principles of Transparency Checklist
Data Policies
Publication Ethics and Publication Malpractice Statement
Sulodexide as a promising treatment of post COVID 19 symptomatic patients with endothelial dysfunction
1
Cardiology department, Hedi Chaker University Hospital Sfax, Tunisia Tunisia
2
Cardiology department, Habib Bourguiba Hospital Medenine, Tunisia
3
Cardiology department, Tahar Sfar Hospital Mahdia, Tunisia
4
Internal medicine department, Mongi Slim LaMarsa Hospital, Tunis, Tunisia Tunisia
5
Cardiology department, Habib Bourguiba Hospital Medenine, Tunisia Tunisia
6
Clinic Pasteur Tunis, Tunisia Tunisia
Publication date: 2023-04-26
Popul. Med. 2023;5(Supplement):A458
ABSTRACT
Background:
It is established that Covid 19 infection causes endothelial dysfunction resulting in most of its acute symptoms and its long-term effects also known as post covid-19 syndrome.
Aim:
The aim of the study was to evaluate the effect of Sulodexide, a purified glycosaminoglycan mixture, in the improvement of the endothelial function due to long COVID 19 syndrome.
Methods:
We conducted a multicenter Tunisian prospective quasi-experimental analysis from the large TUN End-COV trial. Patients with long COVID-19 symptoms and endothelial dysfunction were included. The subset of symptomatic patients with proven endothelial dysfunction (Endothelial Quality Index (EQI)
It is established that Covid 19 infection causes endothelial dysfunction resulting in most of its acute symptoms and its long-term effects also known as post covid-19 syndrome.
Aim:
The aim of the study was to evaluate the effect of Sulodexide, a purified glycosaminoglycan mixture, in the improvement of the endothelial function due to long COVID 19 syndrome.
Methods:
We conducted a multicenter Tunisian prospective quasi-experimental analysis from the large TUN End-COV trial. Patients with long COVID-19 symptoms and endothelial dysfunction were included. The subset of symptomatic patients with proven endothelial dysfunction (Endothelial Quality Index (EQI)
| ISSN: | 2654-1459 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
